Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy.
Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women.
Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M, Li Y, Li S, Lv J.
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
Molecular mechanisms of diabetic cardiomyopathy.
Bugger H, Abel ED.
Diabetologia. 2014 Apr;57(4):660-71. doi: 10.1007/s00125-014-3171-6. Epub 2014 Jan 30.
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.
Park JJ.
Diabetes Metab J. 2021 Mar;45(2):146-157. doi: 10.4093/dmj.2020.0282. Epub 2021 Mar 25.
Oxidative stress and diabetic complications.
Giacco F, Brownlee M.
Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
Type 1 diabetes, its complications, and non-ischemic cardiomyopathy: a mendelian randomization study of European ancestry.
Zhao Y, Quan E, Zeng T, Huang Z, Luo Y, Peng L, Li S, Liu J, Chong Y, Cao H.
Cardiovasc Diabetol. 2024 Jan 13;23(1):31. doi: 10.1186/s12933-023-02117-7.
Nobiletin alleviates myocardial ischemia-reperfusion injury via ferroptosis in rats with type-2 diabetes mellitus.
Huang Q, Tian L, Zhang Y, Qiu Z, Lei S, Xia ZY.
Biomed Pharmacother. 2023 Jul;163:114795. doi: 10.1016/j.biopha.2023.114795. Epub 2023 May 3.
Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?
Hölscher ME, Bode C, Bugger H.
Int J Mol Sci. 2016 Dec 18;17(12):2136. doi: 10.3390/ijms17122136.
Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus.
Sha W, Hu F, Xi Y, Chu Y, Bu S.
J Diabetes Res. 2021 Jun 28;2021:9999612. doi: 10.1155/2021/9999612. eCollection 2021.
Polygenic risk scores for the prediction of cardiometabolic disease.
O'Sullivan JW, Ashley EA, Elliott PM.
Eur Heart J. 2023 Jan 7;44(2):89-99. doi: 10.1093/eurheartj/ehac648.
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S.
JACC Heart Fail. 2024 Jan;12(1):67-78. doi: 10.1016/j.jchf.2023.08.026. Epub 2023 Oct 25.
